Dermata Secures Australian Patent Acceptance for Topical Dermal Filler Delivery System
DRMA is trading near its 52-week low of $1.1 (9.1% above the low).
Summary
Dermata Therapeutics announced the acceptance of its Australian patent application for the topical application of dermal fillers using its Bioneedle Delivery System (BDS). This marks a significant step in strengthening the company's intellectual property for a new application of its core technology. Coming after a recent $15.4 million capital raise and a 10-K filing that included a "going concern" warning, this patent acceptance provides a positive development for the micro-cap company. The CEO highlighted the potential for non-invasive delivery to transform aesthetic treatments, which aligns with Dermata's strategic pivot to direct-to-consumer skincare solutions. The patent is expected to issue in three months unless opposed, with the company planning initial product launches incorporating BDS in mid-2026.
At the time of this announcement, DRMA was trading at $1.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4M. The 52-week trading range was $1.10 to $11.30. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Access Newswire.